 |
PDBsum entry 1a8k
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hydrolase/hydrolase inhibitor
|
PDB id
|
|
|
|
1a8k
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase/hydrolase inhibitor
|
 |
|
Title:
|
 |
Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved ca-p2 substrate: interactions with frequently occurring glutamic acid residue at p2' position of substrates
|
|
Structure:
|
 |
HIV protease. Chain: a, b, d, e. Engineered: yes. Mutation: yes
|
|
Source:
|
 |
Human immunodeficiency virus 1. Organism_taxid: 11676. Expressed in: escherichia coli. Expression_system_taxid: 562
|
|
Biol. unit:
|
 |
Homo-Dimer (from PDB file)
|
|
Resolution:
|
 |
|
2.00Å
|
R-factor:
|
0.174
|
R-free:
|
0.319
|
|
|
Authors:
|
 |
I.T.Weber,J.Wu,J.Adomat,R.W.Harrison,A.R.Kimmel,E.M.Wondrak,J.M.Louis
|
|
Key ref:
|
 |
I.T.Weber
et al.
(1997).
Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.
Eur J Biochem,
249,
523-530.
PubMed id:
|
 |
|
Date:
|
 |
|
27-Mar-98
|
Release date:
|
13-Jan-99
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P03367
(POL_HV1BR) -
Gag-Pol polyprotein from Human immunodeficiency virus type 1 group M subtype B (isolate BRU/LAI)
|
|
|
|
Seq: Struc:
|
 |
 |
 |
1447 a.a.
99 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 3 residue positions (black
crosses)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
E.C.2.7.7.-
- ?????
|
|
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
E.C.2.7.7.49
- RNA-directed Dna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
|
 |
 |
 |
 |
 |
DNA(n)
|
+
|
2'-deoxyribonucleoside 5'-triphosphate
|
=
|
DNA(n+1)
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
E.C.2.7.7.7
- DNA-directed Dna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
|
 |
 |
 |
 |
 |
DNA(n)
|
+
|
2'-deoxyribonucleoside 5'-triphosphate
|
=
|
DNA(n+1)
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 4:
|
 |
E.C.3.1.-.-
|
|
 |
 |
 |
 |
 |
Enzyme class 5:
|
 |
E.C.3.1.13.2
- exoribonuclease H.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Exonucleolytic cleavage to 5'-phosphomonoester oligonucleotides in both 5'- to 3'- and 3'- to 5'-directions.
|
 |
 |
 |
 |
 |
Enzyme class 6:
|
 |
E.C.3.1.26.13
- retroviral ribonuclease H.
|
|
 |
 |
 |
 |
 |
Enzyme class 7:
|
 |
E.C.3.4.23.16
- HIV-1 retropepsin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Specific for a P1 residue that is hydrophobic, and P1' variable, but often Pro.
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
|
Eur J Biochem
249:523-530
(1997)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.
|
|
I.T.Weber,
J.Wu,
J.Adomat,
R.W.Harrison,
A.R.Kimmel,
E.M.Wondrak,
J.M.Louis.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Human immunodeficiency virus type 1 (HIV-1) protease hydrolysis of the Gag CA-p2
cleavage site is crucial for virion maturation and is optimal at acidic pH. To
understand the processing of the CA-p2 site, we have determined the structure of
HIV-1 protease complexed with an analog of the CA-p2 site, the reduced peptide
inhibitor Arg-Val-Leu-r-Phe-Glu-Ala-Ahx-NH2 [r denotes the reduced peptide bond
and Ahx 2-aminohexanoic acid (norleucine), respectively]. The crystal structure
was refined to an R-factor of 0.17 at 0.21-nm resolution. The crystals have
nearly the same lattice as related complexes in P2(1)2(1)2(1) which have twofold
disordered inhibitor, but are in space group P2(1). and the asymmetric unit
contains two dimers of HIV-1 protease related by 180 degrees rotation. An
approximate non-crystallographic symmetry has replaced the exact crystal
symmetry resulting in well-ordered inhibitor structure. Each protease dimer
binds one ordered inhibitor molecule, but in opposite orientations. The
interactions of the inhibitor with the two dimers are very similar for the
central P2 Val to P2' Glu residues, but show more variation for the distal P3
Arg and P4' Ahx residues. Importantly, the carboxylate oxygens of Glu at P2' in
the inhibitor are within hydrogen-bonding distance of a carboxylate oxygen of
Asp30 of the protease suggesting that the two side chains share a proton. This
interaction suggests that the enzyme-substrate complex is additionally
stabilized at lower pH. The importance of this interaction is emphasized by the
absence of polymorphisms of Asp30 in the protease and variants of P2' Glu in the
critical CA-p2 cleavage site.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
R.Ishima,
Q.Gong,
Y.Tie,
I.T.Weber,
and
J.M.Louis
(2010).
Highly conserved glycine 86 and arginine 87 residues contribute differently to the structure and activity of the mature HIV-1 protease.
|
| |
Proteins,
78,
1015-1025.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.D.Altman,
E.A.Nalivaika,
M.Prabu-Jeyabalan,
C.A.Schiffer,
and
B.Tidor
(2008).
Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease.
|
| |
Proteins,
70,
678-694.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
N.Kaushik-Basu,
A.Basu,
and
D.Harris
(2008).
Peptide inhibition of HIV-1: current status and future potential.
|
| |
BioDrugs,
22,
161-175.
|
 |
|
|
|
|
 |
A.Y.Kovalevsky,
A.A.Chumanevich,
F.Liu,
J.M.Louis,
and
I.T.Weber
(2007).
Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate.
|
| |
Biochemistry,
46,
14854-14864.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Prabu-Jeyabalan,
E.A.Nalivaika,
K.Romano,
and
C.A.Schiffer
(2006).
Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate.
|
| |
J Virol,
80,
3607-3616.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
N.Morellet,
S.Druillennec,
C.Lenoir,
S.Bouaziz,
and
B.P.Roques
(2005).
Helical structure determined by NMR of the HIV-1 (345-392)Gag sequence, surrounding p2: implications for particle assembly and RNA packaging.
|
| |
Protein Sci,
14,
375-386.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Y.Tie,
P.I.Boross,
Y.F.Wang,
L.Gaddis,
F.Liu,
X.Chen,
J.Tozser,
R.W.Harrison,
and
I.T.Weber
(2005).
Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
|
| |
FEBS J,
272,
5265-5277.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.Kádas,
I.T.Weber,
P.Bagossi,
G.Miklóssy,
P.Boross,
S.Oroszlan,
and
J.Tözsér
(2004).
Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease.
|
| |
J Biol Chem,
279,
27148-27157.
|
 |
|
|
|
|
 |
M.Prabu-Jeyabalan,
E.A.Nalivaika,
N.M.King,
and
C.A.Schiffer
(2004).
Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease.
|
| |
J Virol,
78,
12446-12454.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.C.Clemente,
R.Hemrajani,
L.E.Blum,
M.M.Goodenow,
and
B.M.Dunn
(2003).
Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
|
| |
Biochemistry,
42,
15029-15035.
|
 |
|
|
|
|
 |
M.Prabu-Jeyabalan,
E.A.Nalivaika,
N.M.King,
and
C.A.Schiffer
(2003).
Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy.
|
| |
J Virol,
77,
1306-1315.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
B.Mahalingam,
P.Boross,
Y.F.Wang,
J.M.Louis,
C.C.Fischer,
J.Tozser,
R.W.Harrison,
and
I.T.Weber
(2002).
Combining mutations in HIV-1 protease to understand mechanisms of resistance.
|
| |
Proteins,
48,
107-116.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Prabu-Jeyabalan,
E.Nalivaika,
and
C.A.Schiffer
(2002).
Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes.
|
| |
Structure,
10,
369-381.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
B.Mahalingam,
J.M.Louis,
J.Hung,
R.W.Harrison,
and
I.T.Weber
(2001).
Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes.
|
| |
Proteins,
43,
455-464.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
B.Mahalingam,
J.M.Louis,
C.C.Reed,
J.M.Adomat,
J.Krouse,
Y.F.Wang,
R.W.Harrison,
and
I.T.Weber
(1999).
Structural and kinetic analysis of drug resistant mutants of HIV-1 protease.
|
| |
Eur J Biochem,
263,
238-245.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
P.Boross,
P.Bagossi,
T.D.Copeland,
S.Oroszlan,
J.M.Louis,
and
J.Tözsér
(1999).
Effect of substrate residues on the P2' preference of retroviral proteinases.
|
| |
Eur J Biochem,
264,
921-929.
|
 |
|
|
|
|
 |
R.Ishima,
D.I.Freedberg,
Y.X.Wang,
J.M.Louis,
and
D.A.Torchia
(1999).
Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function.
|
| |
Structure,
7,
1047-1055.
|
 |
|
|
|
|
 |
J.Wu,
J.M.Adomat,
T.W.Ridky,
J.M.Louis,
J.Leis,
R.W.Harrison,
and
I.T.Weber
(1998).
Structural basis for specificity of retroviral proteases.
|
| |
Biochemistry,
37,
4518-4526.
|
 |
|
PDB codes:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |